# PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT04098796** · PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 30 (estimated)

## Conditions studied

- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP

## Interventions

- **DRUG:** Anti-PD-1 antibody
- **DRUG:** XELOX

## Key facts

- **NCT ID:** NCT04098796
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04098796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04098796, "PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04098796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*